CTKB — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-07

• Total revenue for the three months ended March 31, 2026 was $44.1 million, representing a 6% increase compared to revenue for the three months ended March 31, 2025 of $41.5 million.

• To date, we have adopted a direct sales model in North America, Europe, China, and several other countries in the Asia-Pacific region, and sell our products through third-party distributors in certain countries in Europe, Latin America, the Middle East, Africa and the Asia-Pacific region. Revenue fr…

• We focus a substantial portion of our resources on developing new products and solutions to meet our customers’ needs. Our research and development efforts focus on developing new and complementary instruments, reagents and reagent kits, and continued operating software development. We incurred rese…

• We expect to continue to invest in our commercial infrastructure through hiring additional employees with strong scientific and technical backgrounds to support growth in our instrument sales as well as our planned expansion of reagents offerings and panel design capabilities. We also plan to contin…

• partners. We plan to continue to invest in new product development and enhancements to support our expansion into new markets.

Text removed vs the prior filing · source: 10-Q · 2025-11-05

• Our FSP cell analyzers, the Cytek Aurora, Northern Lights and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and addresses the inherent limitations of other technologies by providing a higher level of multiplexing with exquisite sensitivity, more f…

• On February 28, 2023, we completed the acquisition of certain assets (the “FCI Acquisition”) relating to the flow cytometry and imaging business of Luminex Corporation (“Luminex”), including relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis- and Guava-bra…

• Total revenue for the three and nine months ended September 30, 2025 was $52.3 million and $139.4 million, respectively, representing a 2% increase and a 3% decrease, respectively, compared to revenue for the three and nine

• months ended September 30, 2024 of $51.5 million and $143.0 million, respectively. Total revenue for the three months ended September 30, 2025 increased compared to total revenue for the three months ended September 30, 2024, due to higher service revenue from a larger installed base of instruments …

• To date, we have adopted a direct sales model in North America, Europe, China, and several other countries in the Asia-Pacific region, and sell our products through third-party distributors in certain countries in Europe, Latin America, the Middle East, Africa and the Asia-Pacific region. Revenue fr…

Text added vs the prior filing · source: 10-Q · 2026-05-07

• There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2026 that materially affected, or were reasonably likely to materially affect, our internal control over financia…

Text removed vs the prior filing · source: 10-Q · 2025-11-05

• In connection with our financial statement close process for the year ended December 31, 2024, we identified deficiencies in the control environment and control activities components of the Committee of Sponsoring Organizations (“COSO”) framework that constitute material weaknesses, either individua…

• •Control environment – Management did not maintain an effective control environment based on the criteria established in the COSO framework and identified deficiencies in the principles associated with the control environment of the COSO framework. Specifically, the Company’s resources within its ac…

• •Control activities – Management did not design and implement effective control activities based on the criteria established in the COSO framework and identified deficiencies in the principles associated with the control activities component of the COSO framework. Specifically, these related to: (i)…

• The following material weaknesses were contributing factors: (i) inadequate general information technology controls (“GITCs”) in the areas of access security and program change-management over certain information technology systems that support the Company’s financial reporting processes. Some of ou…

• We remain committed to remediating the control deficiencies that constituted the above material weaknesses by continuing to enhance our internal control over financial reporting. Management has put in place measures aimed at addressing these deficiencies to ensure the material weaknesses are remedia…

Text added vs the prior filing · source: 10-Q · 2026-05-07

• •If we are unable to successfully develop new products, adapt to rapid and significant technological change, respond to introductions of new products by competitors, make strategic and operational decisions to prioritize certain markets, technology offerings or partnerships, and develop and capitali…

• •If we fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations.

• •If our information technology systems or data, or those of third parties with whom we work, are compromised, now or in the future, we could experience adverse consequences resulting from such a

• compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.

• •Concentration of ownership of our common stock among our executive officers, directors, and principal stockholders and their respective affiliates may prevent new investors from influencing significant corporate decisions.

Text removed vs the prior filing · source: 10-Q · 2025-11-05

• information included or incorporated by reference in this Quarterly Report on Form 10-Q. If any of the following risks actually occur, our business, financial condition, results of operations and future prospects could be materially and adversely affected. You should not interpret our disclosure of …

• •Our future success depends on our ability to develop and successfully introduce new and enhanced products that meet the needs of our customers.

• •If we are unable to successfully develop new products, adapt to rapid and significant technological change, respond to introductions of new products by competitors, make strategic and operational decisions to

• prioritize certain markets, technology offerings or partnerships, and develop and capitalize on markets, technologies or partnerships, our business could suffer.

• •New product development involves a lengthy and complex process, and we may be unable to develop or commercialize products on a timely basis, or at all.